• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

COVID-19: Llama antibodies have 'significant potential' as coronavirus treatment with new research hailed

M

Mary Wilson

Well-known member
Wednesday 22 September 2021 11:59, UK

Alexander Martin

Llamas produce a unique kind of antibody which scientists believe could offer a new frontline treatment against COVID-19, administered via a nasal spray.

Nanobodies, a smaller and simpler form of antibody produced by llamas and camels, can effectively target the novel coronavirus, new research published in the journal Nature Communication has found.

Scientists at the Rosalind Franklin Institute in the UK have identified short chains of these molecules that can significantly reduce signs of COVID-19 when given to other infected animals.

https://news.sky.com/story/covid-19...-research-hailed-12414266?dcmp=snt-sf-twitter
 
A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19
Nature Communications volume 12, Article number: 5469 (2021) Cite this article


Abstract


SARS-CoV-2 remains a global threat to human health particularly as escape mutants emerge. There is an unmet need for effective treatments against COVID-19 for which neutralizing single domain antibodies (nanobodies) have significant potential. Their small size and stability mean that nanobodies are compatible with respiratory administration. We report four nanobodies (C5, H3, C1, F2) engineered as homotrimers with pmolar affinity for the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. Crystal structures show C5 and H3 overlap the ACE2 epitope, whilst C1 and F2 bind to a different epitope. Cryo Electron Microscopy shows C5 binding results in an all down arrangement of the Spike protein. C1, H3 and C5 all neutralize the Victoria strain, and the highly transmissible Alpha (B.1.1.7 first identified in Kent, UK) strain and C1 also neutralizes the Beta (B.1.35, first identified in South Africa). Administration of C5-trimer via the respiratory route showed potent therapeutic efficacy in the Syrian hamster model of COVID-19 and separately, effective prophylaxis. The molecule was similarly potent by intraperitoneal injection.

https://www.nature.com/articles/s41467-021-25480-z
 
You must log in or register to reply here.
Back
Top Bottom